News archivo - VIVEbiotech

8 January 2025

VIVEbiotech’s Expertise Highlighted in Drug Discovery World’s 2025 Predictions

Natalia Elizalde shares insights on the future of cell and gene therapy.

20 December 2024

Merry Christmas and Happy New Year from our extraordinary team

As the year winds down, we’re filled with gratitude for the incredible journey that was 2024 for VIVEbiotech.

16 December 2024

VIVEbiotech will be exhibiting at the Advanced Therapies Week in Dallas

VIVEbiotech will be an exhibitor at Phacilitate's Advanced Therapies Week to be held in Dallas from January 20-23.

4 December 2024

VIVEbiotech Secures Growth Investment from Ampersand Capital Partners to Expand Lentiviral Vector Development and Manufacturing Capabilities

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private equity...

25 October 2024

VIVEbiotech publishes new research paper

We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing...

24 October 2024

Active participation of VIVEbiotech at the ESGCT´s 31st annual meeting

The European Society of Gene and Cell Therapy´s annual congress is in full swing.

10 October 2024

VIVEbiotech participates one more year in the Innovative Therapies Days

VIVEbiotech is participating as a Silver Sponsor in Innovative Therapies Days, a 2-day conference that takes place every year in Besançon, in the R�...

8 October 2024

VIVEbiotech participates in Cell & Gene Meeting on the Mesa

As in several past editions, VIVEbiotech is participating in Cell & Gene Meeting on the Mesa.

18 September 2024

Q&A in GEN with Natalia Elizalde

Natalia Elizalde, our Chief Business Development Officer at VIVEbiotech, recently shared her expertise with GEN on the increasing demand for lentiviral vectors, of which we...